Skip to content

XERIS + STRONGBRIDGECreating an Innovative Leader in Endocrinology and Rare Diseases

View Infographic

Xeris Pharmaceuticals, Inc. (“Xeris”) (Nasdaq: XERS) and Strongbridge Biopharma plc (“Strongbridge”) (Nasdaq: SBBP) have entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights. Together they will create a diversified biopharmaceutical company with an enhanced growth profile, well-positioned for long-term product development and commercial success.